Dupont Capital Management Corp Purchases New Position in IDEXX Laboratories, Inc. (IDXX)

Dupont Capital Management Corp purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 1,307 shares of the company’s stock, valued at approximately $285,000.

Several other institutional investors and hedge funds have also modified their holdings of the company. Eqis Capital Management Inc. acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $2,610,000. Scott & Selber Inc. acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $3,902,000. Moody Lynn & Lieberson LLC boosted its holdings in shares of IDEXX Laboratories by 198.2% during the 2nd quarter. Moody Lynn & Lieberson LLC now owns 28,516 shares of the company’s stock valued at $6,215,000 after acquiring an additional 18,954 shares in the last quarter. AGF Investments Inc. boosted its holdings in shares of IDEXX Laboratories by 5,862.3% during the 1st quarter. AGF Investments Inc. now owns 338,001 shares of the company’s stock valued at $64,690,000 after acquiring an additional 332,332 shares in the last quarter. Finally, Oakbrook Investments LLC boosted its holdings in shares of IDEXX Laboratories by 36.6% during the 2nd quarter. Oakbrook Investments LLC now owns 5,643 shares of the company’s stock valued at $1,230,000 after acquiring an additional 1,513 shares in the last quarter. Institutional investors own 86.85% of the company’s stock.

IDXX has been the topic of several recent research reports. Stifel Nicolaus raised their price objective on IDEXX Laboratories from $215.00 to $225.00 and gave the company a “buy” rating in a report on Monday, May 7th. Credit Suisse Group raised their price objective on IDEXX Laboratories from $209.00 to $228.00 and gave the company an “outperform” rating in a report on Friday, June 1st. BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 9th. Zacks Investment Research downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Monday, July 9th. Finally, Canaccord Genuity reissued a “positive” rating and set a $215.00 price objective on shares of IDEXX Laboratories in a report on Monday, May 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $239.33.



In other IDEXX Laboratories news, insider Giovani Twigge sold 1,626 shares of IDEXX Laboratories stock in a transaction dated Tuesday, May 29th. The stock was sold at an average price of $204.37, for a total transaction of $332,305.62. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Jacqueline Studer sold 475 shares of IDEXX Laboratories stock in a transaction dated Wednesday, May 30th. The stock was sold at an average price of $209.98, for a total value of $99,740.50. The disclosure for this sale can be found here. Insiders have sold a total of 10,699 shares of company stock worth $2,515,943 over the last ninety days. Company insiders own 2.56% of the company’s stock.

NASDAQ IDXX opened at $243.37 on Wednesday. The company has a debt-to-equity ratio of -14.77, a quick ratio of 0.73 and a current ratio of 0.96. IDEXX Laboratories, Inc. has a twelve month low of $146.09 and a twelve month high of $252.49. The firm has a market cap of $21.09 billion, a P/E ratio of 74.20, a PEG ratio of 2.22 and a beta of 0.69.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Wednesday, August 1st. The company reported $1.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.17 by $0.06. The firm had revenue of $580.75 million for the quarter, compared to the consensus estimate of $574.68 million. IDEXX Laboratories had a negative return on equity of 703.80% and a net margin of 14.50%. The business’s quarterly revenue was up 14.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.87 EPS. analysts forecast that IDEXX Laboratories, Inc. will post 4.18 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

See Also: Trading Penny Stocks

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply